Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02231749. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Ipilimumab Versus Sunitinib Monotherapy in Subjects With Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to compare the objective response rate, progression free survival and the overall survival of Nivolumab combined with Ipilimumab to Sunitinib monotherapy in patients with previously untreated Renal Cell Cancer.
Study identification
- NCT ID
- NCT02231749
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,096 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 16, 2014 (Actual)
- Primary completion
- Jun 26, 2017 (Actual)
- Completion
- Mar 21, 2025 (Actual)
- Last update posted
- May 27, 2026
2014 – 2025
United States locations
- U.S. sites
- 37
- U.S. states
- 20
- U.S. cities
- 31
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0006 | Duarte | California | 91010 | — |
| Local Institution - 0057 | La Jolla | California | 92093-0698 | — |
| Local Institution - 0044 | Los Angeles | California | 90033 | — |
| Local Institution - 0035 | Los Angeles | California | 90048 | — |
| Local Institution - 0067 | Stanford | California | 94305 | — |
| Local Institution - 0138 | New Haven | Connecticut | 06520 | — |
| Local Institution - 0034 | Washington D.C. | District of Columbia | 20007 | — |
| Local Institution - 0049 | Tampa | Florida | 33612 | — |
| Local Institution - 0068 | Atlanta | Georgia | 30322 | — |
| Local Institution - 0038 | Indianapolis | Indiana | 46202 | — |
| Local Institution - 0042 | Iowa City | Iowa | 52242 | — |
| Local Institution - 0163 | Fairway | Kansas | 66205 | — |
| Local Institution - 0048 | Baltimore | Maryland | 21201 | — |
| Local Institution - 0004 | Baltimore | Maryland | 21287 | — |
| Local Institution - 0135 | Boston | Massachusetts | 02111 | — |
| Local Institution - 0110 | Boston | Massachusetts | 02215 | — |
| Local Institution - 0161 | Boston | Massachusetts | 02215 | — |
| Local Institution - 0173 | Boston | Massachusetts | 02215 | — |
| Local Institution - 0046 | Ann Arbor | Michigan | 48109 | — |
| Local Institution - 0043 | Detroit | Michigan | 48201 | — |
| Local Institution - 0036 | Buffalo | New York | 14263 | — |
| Local Institution - 0001 | New York | New York | 10065 | — |
| Local Institution - 0008 | Charlotte | North Carolina | 28204 | — |
| Local Institution - 0045 | Durham | North Carolina | 27710 | — |
| Local Institution - 0007 | Cleveland | Ohio | 44195 | — |
| Local Institution - 0164 | Columbus | Ohio | 43210 | — |
| Local Institution - 0039 | Portland | Oregon | 97239 | — |
| Local Institution - 0054 | Allentown | Pennsylvania | 18105 | — |
| Local Institution - 0005 | Philadelphia | Pennsylvania | 19111 | — |
| Local Institution - 0031 | Pittsburgh | Pennsylvania | 15232 | — |
| Local Institution - 0055 | Charleston | South Carolina | 29425 | — |
| Local Institution - 0159 | Chattanooga | Tennessee | 37403 | — |
| Local Institution - 0066 | Nashville | Tennessee | 37203 | — |
| Local Institution - 0056 | Dallas | Texas | 75246 | — |
| Local Institution - 0032 | Dallas | Texas | 75390-8852 | — |
| Local Institution - 0003 | Houston | Texas | 77030-4009 | — |
| Local Institution - 0041 | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 152 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02231749, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 27, 2026 · Synced Nov 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.